The Group's principal activities are researching and developing biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of its gene delivery technology include gene therapies for cancer, DNA vaccines for infectious diseases or cancer, and DNA therapeutic protein delivery. It has retained all rights to its internally developed cancer product candidates. In addition, it collaborates with major pharmaceutical and biotechnology companies that give access to complementary technologies or greater resources. These strategic partnerships provide mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs.
Alacra Alerts:
Receive alerts on the latest reports on Vical Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
